- Home
- BMRA vs GRI Comparison
BMRA vs GRI Comparison
Compare BMRA & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- GRI
- Stock Information
- Founded
- BMRA 1971
- GRI 2018
- Country
- BMRA United States
- GRI United States
- Employees
- BMRA N/A
- GRI N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- GRI Health Care
- Exchange
- BMRA Nasdaq
- GRI Nasdaq
- Market Cap
- BMRA 5.9M
- GRI 6.1M
- IPO Year
- BMRA N/A
- GRI N/A
- Fundamental
- Price
- BMRA $0.64
- GRI $0.72
- Analyst Decision
- BMRA
- GRI Strong Buy
- Analyst Count
- BMRA 0
- GRI 2
- Target Price
- BMRA N/A
- GRI $11.50
- AVG Volume (30 Days)
- BMRA 20.4M
- GRI 182.9K
- Earning Date
- BMRA 01-14-2025
- GRI 11-14-2024
- Dividend Yield
- BMRA N/A
- GRI N/A
- EPS Growth
- BMRA N/A
- GRI N/A
- EPS
- BMRA N/A
- GRI N/A
- Revenue
- BMRA $5,578,000.00
- GRI N/A
- Revenue This Year
- BMRA N/A
- GRI N/A
- Revenue Next Year
- BMRA N/A
- GRI N/A
- P/E Ratio
- BMRA N/A
- GRI N/A
- Revenue Growth
- BMRA 1.40
- GRI N/A
- 52 Week Low
- BMRA $0.24
- GRI $0.30
- 52 Week High
- BMRA $1.35
- GRI $65.00
- Technical
- Relative Strength Index (RSI)
- BMRA 73.05
- GRI 44.58
- Support Level
- BMRA $0.29
- GRI $0.68
- Resistance Level
- BMRA $1.27
- GRI $0.77
- Average True Range (ATR)
- BMRA 0.09
- GRI 0.07
- MACD
- BMRA 0.04
- GRI -0.01
- Stochastic Oscillator
- BMRA 36.36
- GRI 16.44
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.